Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Idorsia in the transaction. Idorsia Ltd (SIX:IDIA) announced that it entered into an agreement with Janssen Biotech Inc., one of...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
You must be a Standard 1 Year member to access this content.
